Skip to main content

Study to Assess Adverse Events and How Intravenous (IV) or Subcutaneous (SC) ABBV-382 Moves Through the Body of Adult Participants With Human Immuno-Deficiency Virus (HIV-1)

Completed · Phase 1 · NCT04554966

Conditions: Human Immunodeficiency Virus (HIV)

At a glance

Research payments reported, 2025
$78,984
U.S. investigators named
2
Sites paid
2
Planned or actual enrollment
54

About the trial

Sponsor
AbbVie
Tested
ABBV-382 (drug), ABBV-382 (drug), Placebo for ABBV-382 (drug)
Dates
Started 2021-04-16; completion 2023-08-14
Results posted
Not yet

Human immuno-deficiency virus (HIV) is the virus that causes Acquired Immuno-Deficiency Syndrome (AIDS). HIV infection is considered to be a chronic disease requiring lifelong therapy. This study will evaluate how safe ABBV-382 is and how it is absorbed, distributed and eliminated from the body in adult participants with HIV-1 infection. ABBV-382 is an investigational drug being developed for the treatment of HIV-1 infection. This study takes place in 2 parts. In Part A, participants with HIV-1 and no history of combination antiretroviral therapy (cART) or who are off cART for more than 3 months will be enrolled to receive ABBV-382. In Part B, participants with no virus in their blood and…

From ClinicalTrials.gov, last updated 2024-03-04. Full record, eligibility and contacts (opens in a new tab)

Industry funding

AbbVie Inc. reported $78,984 in research payments for this study in 2025 (2 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Lalezari Medical Corporation $50,228
  • Infinite Clinical Trials $28,756

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.